Status:
COMPLETED
Functional Residual Capacity During Different Levels of High-flow in Preterm Infants
Lead Sponsor:
University of Zurich
Conditions:
Infant, Premature, Diseases
Respiratory Distress Syndrome
Eligibility:
All Genders
73+ years
Phase:
NA
Brief Summary
Although there is a widespread use of HighFlow therapy around the world, there is still uncertainty about the most appropriate initial HighFlow level after nasal continuous positive airway pressure th...
Eligibility Criteria
Inclusion
- Written Informed Consent by one or both parents or legal guardians as documented by signature
- 30 - 35 weeks postmenstrual age
- Respiratory support with nCPAP PEEP 5mbar and FiO2 \< 0.30
- \> 72 hours old
Exclusion
- Inability of the parents to understand the study concept or procedures due to cognitive or linguistic reasons
- Congenital malformations adversely affecting lung aeration or pulmonary perfusion (e.g. congenital heart or lung defects)
Key Trial Info
Start Date :
February 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05237622
Start Date
February 19 2022
End Date
January 13 2023
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Newborn Research, Department of Neonatology, University Hospital Zurich
Zurich, Switzerland, 8091